All the Active Ingredient Drugs
Human Hepatitis B Immunoglobulin 50 IU/ml. AMPS: 2 ml.
VIALS: 10 ml, 40 ml. Aft. infect: 0.12 ml -
0.20 ml (6 IU - 10 IU)/kg bdy. wt. Proph.
(in high risk): Inject 0.14 ml (7 IU)/kg
bdy. wt. aft. screen. for HbsAg and
anti-HBs. Repeat at 2 mth. intervals.
See lit. Proph. in newborns og HBsantigen
positive mothers: 0.4 ml (20
IU)/kg bdy. wt. immed. aft. birth. See
Proph. against hepatit. B in adults and
child over 2 yrs. who have not been
vaccinat. against hepatit. B (incl. persons
whose vaccinat. is incomplete or missing),
at risk by accident. contact e.g. accident.
needle stick or direct mucous membrane
contact when admin. of I.M. hepatit.
immunoglob. is not possible. To be admin.
with hepatit. B vaccine. Immunoproph.
hepatit. B in newborn of hepatit. B virus
C/I: Hypersens. to homologous
Human Hepatitis B Immunoglobulin 50 IU/ml. I.V. VIAL: 1 x 100 ml x 50 IU/ml anti
HBsAg. 10,000 IU in anhepatic stage
(OLT foll. by 10,000 IU dly for 1st 5-7
days) aft. transplant. See lit.
Passive. immunizant. prevent hepatit. B
re-infect. aft. liver transplant. See lit.
C/I: Anaphylact. or severe system.
response to I.M./I.V. immunoglob. preps.
Not to be given with antibodies
to IgA or selective IgA defic.